Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Sponsor: Genentech, Inc.
A PHASE2 clinical study on Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 9 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Seagen Inc.
For direct contact, visit the study record on ClinicalTrials.gov .